Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Reducing the stigma of long acting injectable antipsychotics: current concepts and future developments
Luleå University of Technology, Department of Health Sciences, Medical Science.ORCID iD: 0000-0002-0654-5410
Maudsley Hospital, Pharmacy Department .
Division of Psychiatry, Sunderby Research Unit, Department of Clinical Sciences, Umeå University.
2018 (English)In: Conference proceedings of the 4th Masterclass Psychiatry: Transcultural Psychiatry – Diagnostics and Treatment, Luleå, Sweden, 22–23 February 2018 (Region Norrbotten in collaboration with the Maudsley Hospital and Tavistock Clinic London) / [ed] Ursula Werneke, Taylor & Francis, 2018, p. 30-33Conference paper, Published paper (Refereed)
Abstract [en]

Background: Long acting injectable antipsychotics (LAIAPs) are considered a major advance in psychiatric treatment concerning treatment adherence and outcomes. Yet, both, doctors and patients, remain sceptical.

Aim: To explain the rationale for using LAI-APs, review their effectiveness and explore barriers to use. Method: Clinical overview of LAI-APs from the patient and doctor perspective.

Results: LAI-APs were developed to increase adherence to treatment, thereby improving treatment outcomes. LAI-APs may reduce risk of relapse and hospitalization. Yet, the evidence from the few meta-analyses available remains weak. Both patients and doctors may associate LAI-APs with stigma and coercion. Current means of improving adherence include more focus on the therapeutic relationship, better information, adverse effects minimization and halflife extension of LAI-APs. Future means of improving adherence include novel administration techniques that abolish the need for injection.

Conclusions: For both, clinicians and drug developers, drug adherence remains a major target for improving treatment outcomes.

Place, publisher, year, edition, pages
Taylor & Francis, 2018. p. 30-33
Series
Nordic Journal of Psychiatry, ISSN 0803-9488, E-ISSN 1502-4725 ; Volume 72, Supp 1
Keywords [en]
Antipsychotics, long-acting injections, adherence, relapse, blood–brain barrier
National Category
Other Medical Engineering
Identifiers
URN: urn:nbn:se:ltu:diva-72856DOI: 10.1080/08039488.2018.1481525Scopus ID: 2-s2.0-8505870245OAI: oai:DiVA.org:ltu-72856DiVA, id: diva2:1287829
Conference
Transcultural Psychiatry – Diagnostics and Treatment; Luleå, Sweden; 22–23 February 2018
Available from: 2019-02-12 Created: 2019-02-12 Last updated: 2020-02-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Velaga, Sitaram

Search in DiVA

By author/editor
Velaga, Sitaram
By organisation
Medical Science
Other Medical Engineering

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 20 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf